Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other financing activities (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Other financing activities for 13 consecutive years, with $4000.0 as the latest value for Q4 2025.

  • Quarterly Other financing activities rose 100.17% to $4000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, up 1961.84% year-over-year, with the annual reading at $1.6 million for FY2025, 1961.84% up from the prior year.
  • Other financing activities for Q4 2025 was $4000.0 at Anika Therapeutics, down from $13000.0 in the prior quarter.
  • The five-year high for Other financing activities was $2.3 million in Q1 2024, with the low at -$2.3 million in Q4 2024.
  • Average Other financing activities over 5 years is $140500.0, with a median of $59500.0 recorded in 2022.
  • The sharpest move saw Other financing activities soared 1454.17% in 2021, then plummeted 328.04% in 2022.
  • Over 5 years, Other financing activities stood at $403000.0 in 2021, then tumbled by 328.04% to -$919000.0 in 2022, then tumbled by 88.79% to -$1.7 million in 2023, then tumbled by 32.22% to -$2.3 million in 2024, then soared by 100.17% to $4000.0 in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at $4000.0, $13000.0, and $83000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.